|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Specifically, we assemble and examine three genetic clusters relevant to non-demented cognitive trajectories: 1) Apolipoprotein E (APOE), 2) a Cognitive Aging Genetic Risk Score (CA-GRS; Catechol-O-methyltransferase + Brain-derived neurotrophic factor), and 3) an AD-Genetic Risk Score (AD-GRS; Clusterin + Complement receptor 1 + Phosphatidylinositol-binding clathrin assembly protein).
|
29480189 |
2018 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Changes in the CLU gene locus are highly associated with Alzheimer disease, and many therapy-resistant cancers over-express CLU.
|
27978767 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
|
28199971 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
No association was observed for CLU and PICALM with AD.
|
28558900 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine whether the variants of some candidate genes involved in the development of AD, namely BIN1 (rs744373), CLU (rs11136000), CR1 (rs3818361), and PICALM (rs3851179), are related to several disorders of glucose metabolism-gestational diabetes (GDM), T2DM and impaired glucose tolerance (IGT).
|
28316001 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
To examine whether a polygenic risk score (PRS) derived from <i>APOE4, CLU,</i> and <i>ABCA7</i> is associated with CSF biomarkers of Alzheimer disease (AD) pathology and whether higher cardiorespiratory fitness (CRF) modifies the association between the PRS and CSF biomarkers.
|
28341646 |
2017 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Plasma clusterin level showed an association with overall AD polygenic risk score, while clusterin, C1inh, and CRP levels each displayed some association with the inflammatory-specific AD polygenic risk score.
|
27911318 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The CLU gene could consistently affect the DMN FC with frontal regions among individuals at risk for Alzheimer's disease, and the CLU-T allele was associated with more compensatory neural processes in DMN changes.
|
28233427 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the functional significance of a clusterin intronic SNP, rs2279590, that has been associated with pseudoexfoliation, Alzheimer's disease (AD) and diabetes.
|
28973302 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E (APOE) ɛ4 and Clusterin (CLU) C alleles are risk factors for Alzheimer's disease (AD) and episodic memory (EM) decline.
|
28025282 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that SNPs in CLU are potential markers for MCI to AD progression.
|
26976043 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings reveal that clusterin is upregulated by Aβ and is responsive to AD pathology, although plasma clusterin concentration is not evidenced to be a stand-alone biomarker for AD.
|
28558636 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The clinical significance of plasma clusterin and Aβ in AD progression remains controversial.
|
29169407 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD.
|
28508031 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the TH and WM (areas with little amyloid pathology) clusterin was unaltered in AD and did not correlate with Aβ level.
|
27248362 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis demonstrated that the rs9331888/C > G polymorphism in the clusterin gene might contribute to AD susceptibility especially in Caucasian populations.
|
28168383 |
2017 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Clusterin (apolipoprotein J or ApoJ) is a complement inhibitor that appears to have a neuroprotective effect in response to tissue damage and has been reported to be upregulated in Alzheimer's disease.
|
27365216 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
By contrast, genetic risk for Alzheimer disease (AD) was associated with worse item and associative memory, indicating adverse effects of APOE ε4 and a genetic risk score for AD (PICALM, BIN1, CLU) on episodic memory in general.
|
27647283 |
2017 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analyses of known AD risk loci suggest CLU and FERMT2 may influence CSF Aβ<sub>42</sub> (P = 0.001 and P = 0.009, respectively) and the INPP5D locus may affect ptau<sub>181</sub> levels (P = 0.009); larger studies are necessary to verify these results.
|
28247064 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings suggest that in the absence of CLU, Aβ clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.
|
28701379 |
2017 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that the level of clusterin protein but not mRNA is reduced in the brains of 3xTg-AD mice.
|
28396259 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings add to the evidence that the CLU gene may represent a potential therapeutic target for slowing disease progression in AD.
|
26899953 |
2016 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, little was known about the possible effect of CLU genetic variants on AD pathology in brain.
|
27229352 |
2016 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that clusterin (CLU), which is also known as apolipoprotein J, is involved in the pathogenesis of Alzheimer disease (AD).
|
27076484 |
2016 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Whereas the APOE4 frequency was higher in AD (p < 0.001) and CAA (p = 0.013), the APOA1 and CLU genotypes were not different among groups.
|
26661731 |
2016 |